Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
作者信息
Bocci Guido, Di Paolo Antonello, Barbara Cecilia, Masi Gianluca, Fornaro Lorenzo, Loupakis Fotios, Allegrini Giacomo, Falcone Alfredo, Del Tacca Mario, Danesi Romano
出版信息
Br J Clin Pharmacol. 2009 Jan;67(1):132-4. doi: 10.1111/j.1365-2125.2008.03307.x. Epub 2008 Nov 5.
Abstract
摘要
相似文献
1
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
Br J Clin Pharmacol. 2009 Jan;67(1):132-4. doi: 10.1111/j.1365-2125.2008.03307.x. Epub 2008 Nov 5.
2
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Clin Pharmacol Ther. 2006 Oct;80(4):384-95. doi: 10.1016/j.clpt.2006.06.007.
3
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
Pharmacogenomics. 2013 May;14(7):799-811. doi: 10.2217/pgs.13.54.
4
[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].
Bull Cancer. 2018 Sep;105(9):790-803. doi: 10.1016/j.bulcan.2018.06.008. Epub 2018 Aug 10.
5
Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
Eur J Med Res. 2003 May 30;8(5):226-8.
6
7
Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Chronobiol Int. 2002 Jan;19(1):177-89. doi: 10.1081/cbi-120002597.
8
Screening for dihydropyrimidine dehydrogenase deficiency.
Clin Cancer Res. 2005 Jul 15;11(14):5067-8. doi: 10.1158/1078-0432.CCR-05-0769.
9
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Ann Oncol. 2001 Sep;12(9):1301-6. doi: 10.1023/a:1012294617392.
引用本文的文献
1
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.
Br J Clin Pharmacol. 2016 Jan;81(1):124-30. doi: 10.1111/bcp.12790. Epub 2015 Nov 28.
2
In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity.
Pharm Res. 2013 May;30(5):1281-90. doi: 10.1007/s11095-012-0967-2. Epub 2013 Feb 6.
3
A practical approach for assessing chemosensitivity in colorectal cancer cell lines by comparative analysis of cell viability and thymidylate synthase mRNA expression.
J Korean Surg Soc. 2012 Jan;82(1):28-34. doi: 10.4174/jkss.2012.82.1.28. Epub 2011 Dec 27.
4
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.
Cancer Chemother Pharmacol. 2011 Dec;68(6):1611-7. doi: 10.1007/s00280-011-1661-5. Epub 2011 May 18.
本文引用的文献
1
Predicting fluorouracil toxicity: can we finally do it?
J Clin Oncol. 2008 May 1;26(13):2080-2. doi: 10.1200/JCO.2007.15.5481. Epub 2008 Feb 25.
2
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Clin Colorectal Cancer. 2006 Nov;6(4):288-96. doi: 10.3816/CCC.2006.n.047.
3
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Clin Pharmacol Ther. 2006 Oct;80(4):384-95. doi: 10.1016/j.clpt.2006.06.007.
4
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8699-705. doi: 10.1158/1078-0432.CCR-05-1520.
5
Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.
Clin Cancer Res. 2005 Jul 15;11(14):5104-11. doi: 10.1158/1078-0432.CCR-05-0217.
6
A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
J Clin Pharm Ther. 2004 Aug;29(4):307-15. doi: 10.1111/j.1365-2710.2004.00569.x.
7
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
Clin Cancer Res. 2004 Apr 15;10(8):2652-8. doi: 10.1158/1078-0432.ccr-03-0374.
8
Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.
Genet Test. 2003 Summer;7(2):97-105. doi: 10.1089/109065703322146777.
9
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Eur J Clin Pharmacol. 2002 Dec;58(9):593-5. doi: 10.1007/s00228-002-0534-6.
10
Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jul 15;774(2):223-30. doi: 10.1016/s1570-0232(02)00239-8.
Zotero 插件